OB/GYN & Women’s Health

Tamoxifen and Uterine Disease Risk in Young Breast Cancer Survivors: Evidence from a Target Trial Emulation Study

By MedXY 03/13/2026

A large-scale cohort study of premenopausal women demonstrates that adjuvant tamoxifen significantly increases the risk of endometrial cancer, hyperplasia, and polyps, with risk correlating to treatment duration.

Clinical Updates Diabetes & Endocrinology news OB/GYN & Women's Health

Lifestyle Determinants and Metabolic Compensation in Pregnancies Complicated by Type 1 Diabetes: A Synthesis of the ENDIA Study and Recent Evidence

By MedXY 03/12/2026

This review analyzes the lifestyle patterns of pregnant women with type 1 diabetes, synthesizing findings from the ENDIA study with recent evidence on nutritional adequacy, islet autoimmunity, and the molecular mechanisms of metabolic compensation.

news OB/GYN & Women's Health Oncology

Rethinking Frontline Standards: SONIA Trial Finds No Survival Benefit for First-Line CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

By MedXY 03/12/2026

The Phase 3 SONIA trial demonstrates that delaying CDK4/6 inhibitors to the second-line setting for advanced breast cancer yields comparable overall survival to first-line use, while significantly reducing treatment-related toxicities and healthcare costs.

Clinical Updates news OB/GYN & Women's Health Orthopedics

Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis

By MedXY 03/10/2026

This review analyzes the LIDA trial findings, demonstrating that an abbreviated 3-month romosozumab course followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing costs and treatment burden.

Clinical Updates news OB/GYN & Women's Health Orthopedics

Abbreviated Romosozumab Regimens in Postmenopausal Osteoporosis: A Review of the LIDA Trial and the Shift Toward Precision Anabolic Dosing

By MedXY 03/09/2026

This review evaluates the LIDA trial's findings that 3 months of romosozumab followed by denosumab is non-inferior to 12 months of romosozumab, offering a cost-effective strategy to mitigate long-term side effects.

Clinical Updates Diabetes & Endocrinology news OB/GYN & Women's Health

Management of Graves’ Disease During Pregnancy: Clinical Insights from the Danish PRETHYR Multicenter Study

By MedXY 03/09/2026

This clinical review synthesizes findings from the PRETHYR study on antithyroid drug use in pregnant women, highlighting treatment transitions, biochemical predictors, and the impact of specialist-led management in Denmark.

news OB/GYN & Women's Health Oncology Radiology

Adjunctive Ultrasonography Reduces Advanced Breast Cancer Risk in Women Aged 40-49: Long-Term Evidence from J-START

By MedXY 02/25/2026

A prespecified secondary analysis of the J-START trial reveals that adding ultrasonography to mammography for women aged 40-49 significantly reduces the long-term cumulative incidence of advanced breast cancer, particularly in populations where dense breast tissue is prevalent.

Cardiology news OB/GYN & Women's Health

Pregnancy as a Window to Longevity: Maternal Biomarkers at 29 Weeks Predict Long-Term Cardiovascular Risk

By MedXY 02/20/2026

A Danish cohort study demonstrates that specific pregnancy biomarkers, particularly sFlt-1 and hs-cTnI measured at 29 weeks, significantly enhance the prediction of long-term cardiovascular disease risk in women, independent of traditional clinical factors and hypertensive disorders of pregnancy.

news OB/GYN & Women's Health

Scheduled Early-Term Birth: A Proven Strategy to Prevent Pre-eclampsia in High-Risk Pregnancies

By MedXY 01/08/2026

The PREVENT-PE trial demonstrates that risk-stratified scheduled birth at 37–38 weeks reduces pre-eclampsia incidence by 30% without increasing neonatal morbidity or emergency cesarean sections, offering a new standard for late-pregnancy management.

news OB/GYN & Women's Health

Manchester Procedure and Sacrospinous Hysteropexy Yield Equivalent Sexual Function Outcomes in Uterine Prolapse Repair

By MedXY 12/27/2025

This randomized clinical trial analysis confirms that both the Manchester procedure and sacrospinous hysteropexy significantly improve sexual function in women with uterine prolapse, with equivalent outcomes and low rates of de novo dyspareunia at 24 months.

Dermatology news OB/GYN & Women's Health

EMG-Guided Botulinum Toxin Injections Significantly Reduce Pain and Improve Sexual Function in Provoked Vestibulodynia

By MedXY 12/27/2025

A randomized double-blind trial reveals that EMG-guided Onabotulinum toxin A injections effectively alleviate pain and enhance quality of life and sexual satisfaction in women with provoked vestibulodynia, supporting the role of muscular hypertonicity in the condition's pathophysiology.

news OB/GYN & Women's Health Public Health

Preconception Trace Metal Profiles in Couples: A New Frontier in Optimizing IVF Embryological Outcomes

By MedXY 12/27/2025

A prospective study of 1071 couples identifies that plasma trace metal concentrations in both partners significantly influence IVF success, with elements like iron and molybdenum showing benefits while silver and thallium pose risks to embryo quality.

Diabetes & Endocrinology news OB/GYN & Women's Health

One in Four Premenopausal Women with Type 1 Diabetes Faces Undiagnosed Androgen Excess Disorders

By MedXY 12/27/2025

A cross-sectional study reveals that 26% of women with Type 1 Diabetes suffer from undiagnosed androgen excess, primarily PCOS. The findings emphasize the role of iatrogenic hyperinsulinism and advocate for routine screening, especially for those with premenarcheal diabetes onset.

Clinical Updates news OB/GYN & Women's Health

Emerging Environmental Threats to Ovarian Reserve: The Association Between Novel PFAS Exposure and Premature Ovarian Insufficiency

By MedXY 12/26/2025

This review synthesizes recent clinical evidence identifying novel per- and poly-fluoroalkyl substances (PFAS) as significant risk factors for premature ovarian insufficiency (POI), highlighting their impact on ovarian reserve markers and endocrine health.

news OB/GYN & Women's Health

Cumulative Live Birth Rates Plateau at 21–25 Oocytes: New Insights from Follitropin Delta Trials

By MedXY 12/26/2025

A pooled analysis of 1,746 patients demonstrates that while fresh cycle success peaks early, cumulative live birth rates continue to rise with oocyte yield, plateauing at 21–25 oocytes. This benefit is most pronounced in patients aged 38 and older, suggesting age-specific stimulation targets.

news OB/GYN & Women's Health

Does Size Matter? Re-evaluating Endometrial Thickness Thresholds in 30,000 Euploid Embryo Transfers

By MedXY 12/26/2025

An international multicenter study confirms that endometrial thickness below 7 mm reduces live birth rates in most frozen embryo transfer protocols, though the impact is notably absent in natural cycles and overall predictive power remains modest.

news OB/GYN & Women's Health

Challenging the Compaction Paradigm: Why Endometrial Thinning May Not Predict Pregnancy Success in HRT-FET

By MedXY 12/26/2025

A large-scale analysis of over 16,000 cases reveals that endometrial compaction following progesterone administration does not improve pregnancy outcomes in HRT-FET, and may even be associated with lower success rates in blastocyst transfers.

news OB/GYN & Women's Health

Live Birth Rates Independent of Sex-Steroid Levels in Dydrogesterone-Based Programmed-Ovulatory FET: A Shift in Luteal Support Monitoring?

By MedXY 12/26/2025

A multicentric study demonstrates that sex-steroid levels on the day of embryo transfer do not predict live birth rates in a novel programmed-ovulatory FET protocol using dydrogesterone, suggesting that routine hormonal monitoring may be unnecessary when corpus luteum function is preserved.

news OB/GYN & Women's Health Psychiatry

Benzodiazepine Exposure and Adverse Pregnancy Outcomes: New Evidence from a Large-Scale Target Trial Emulation

By MedXY 12/25/2025

A large-scale cohort study emulating randomized trials indicates that benzodiazepine use during pregnancy significantly increases the risk of abortion and preterm birth, even after accounting for competing risks and maternal factors. Risks were most pronounced with second-trimester exposure.

news OB/GYN & Women's Health

ICSI vs. Conventional IVF: New Evidence Suggests No Kinetic Advantage and Lower High-Quality Blastocyst Yield in Non-Male Factor Infertility

By MedXY 12/25/2025

A secondary analysis of the multicentre INVICSI RCT reveals that ICSI results in fewer high-quality Day 5 blastocysts compared to conventional IVF in patients without severe male factor infertility, with no significant differences observed in embryo morphokinetics or cleavage patterns.